Node-positive Nonmetastatic Prostate Cancer: Time to Reconsider Prognostic Staging?

Ashwin Shinde; Richard Li; Scott Glaser; Arya Amini

doi:10.1016/j.eururo.2018.09.017

Node-positive Nonmetastatic Prostate Cancer: Time to Reconsider Prognostic Staging?

Eur Urol. 2019 Mar;75(3):355-357. doi: 10.1016/j.eururo.2018.09.017. Epub 2018 Sep 24.

Authors

Ashwin Shinde¹, Richard Li¹, Scott Glaser¹, Arya Amini²

Affiliations

¹ Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, USA.
² Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, USA. Electronic address: aamini@coh.org.

PMID: 30262339
DOI: 10.1016/j.eururo.2018.09.017

Abstract

Node-positive nonmetastatic prostate cancer is currently prognosticated as stage IV, despite evidence that a proportion of this patient population can be cured. We provide evidence and request reconsideration of prognostic staging in the next edition of the American Joint Committee on Cancer staging manual.

Publication types

Editorial

MeSH terms

Chemotherapy, Adjuvant
Clinical Decision-Making
Databases, Factual
Humans
Lymph Nodes / pathology*
Male
Neoplasm Staging / methods*
Predictive Value of Tests
Prostatectomy
Prostatic Neoplasms / classification
Prostatic Neoplasms / mortality
Prostatic Neoplasms / pathology*
Prostatic Neoplasms / therapy
Radiotherapy, Adjuvant
Risk Factors
Time Factors
Treatment Outcome
United States